| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 93,08 | 94,98 | 09:25 | |
| 93,76 | 94,20 | 13.06. |
Das irische Pharmaunternehmen trotzt der allgemein schwachen Entwicklung der Wall Street und zeigt seit geraumer Zeit Relative Stärke gegenüber dem Gesamtmarkt.Den vollständigen Artikel lesen ...| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® | ||
| Di | Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca | ||
| Di | Jazz Pharma Says FDA Granted Priority Review For Zepzelca And Tecentriq Combo For ES-SCLC | ||
| Di | Jazz Pharmaceuticals plc: Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer | Target Action (PDUFA) Date set for October 7, 2025
Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically... ► Artikel lesen | |
| Di | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 | First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium... ► Artikel lesen |
